GlobeNewswire Inc | Nov 11, 2020 04:05PM EST

November 11, 2020

SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced thatJeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in two upcoming conferences: the Stifel 2020 Virtual Healthcare Conference and 3rd Annual Evercore ISI HealthCONx Conference.

Stifel 2020 Virtual Health Conference

Date: Tuesday, November 17, 2020Time: 2:00 PM Eastern TimeFormat: Presentation

A live audio webcast of the presentation will be available in the Investors section on the Companys website atwww.cidara.com.

3rd Annual Evercore ISI HealthCONx Conference

Date: Wednesday, December 2, 2020Time: 11:20 AM Eastern TimeFormat: Panel Discussion - No Fungus Among Us: Addressing an Important Fungal Need

About Cidara TherapeuticsCidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Companys portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) for the prevention and treatment of influenza and other viral diseases from Cidaras proprietary Cloudbreak antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

INVESTOR CONTACT:Brian RitchieLifeSci Advisors(212) 915-2578britchie@lifesciadvisors.com

MEDIA CONTACT:Karen OShea, Ph.D.LifeSci Communications(929) 469-3860koshea@lifescicomms.com